In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?
Excess Intake of Ultraprocessed Foods Tied to Higher Cardiometabolic Risk, AHA Advisory Says
The advisory panel laid out 4 priority actions for clinicians, policymakers, and industry.
The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment
Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.
Only 1 in 5 Women Meet Heart Health Targets at Midlife, and These 4 Factors Matter Most
Adequate sleep tops the 4 elements most important to CV health after menopause, with blood pressure, glucose levels, and smoking status close behind.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Tirzepatide Proves Noninferiority With Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off
In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.
GLP-1 RAs vs Metformin Significantly Reduce Risk of Dementia in Adults with Type 2 Diabetes
Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.